BL Pharmtech비엘팜텍
065170 · KOSDAQ · ₩065170 · 비엘팜텍
₩1,767▼ ₩103 (5.51%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩6.5B | ₩8.8B | ₩25B | ₩81B | ₩84B |
| Cost of sales | ₩2.8B | ₩2.9B | ₩11B | ₩63B | ₩63B |
| Gross profit | ₩3.7B | ₩5.9B | ₩14B | ₩18B | ₩21B |
| Operating income | −₩2.8B | −₩3.2B | −₩6.8B | −₩2.8B | −₩3.4B |
| Net income | −₩17B | −₩5.7B | ₩142M | −₩14B | −₩20B |
| Net income to shareholders | −₩17B | −₩5.7B | −₩149M | −₩14B | −₩20B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩18B | ₩36B | ₩45B | ₩104B | ₩130B |
| Current assets | ₩8.6B | ₩6.9B | ₩17B | ₩33B | ₩42B |
| Cash and equivalents | ₩7.2B | ₩3.9B | ₩11B | ₩5B | ₩22B |
| Total liabilities | ₩10B | ₩12B | ₩13B | ₩63B | ₩65B |
| Current liabilities | ₩9B | ₩6.6B | ₩8B | ₩49B | ₩37B |
| Borrowings | ₩4.5B | ₩5.2B | ₩3.8B | ₩42B | ₩41B |
| Total equity | ₩7.9B | ₩24B | ₩32B | ₩41B | ₩66B |
| Shareholders' equity | ₩7.9B | ₩24B | ₩31B | ₩34B | ₩58B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩284M | −₩3B | ₩8B | −₩11B | ₩3.1B |
| Capital spending | — | ₩1.2B | ₩312M | ₩1.7B | ₩587M |
| Free cash flow | −₩284M | −₩4.2B | ₩7.7B | −₩13B | ₩2.5B |
Consolidated where available. Amounts in won.
Also known as: BL Pharmtech / 비엘팜텍 / 065170 / KRX:065170
Source: KRX statistical information